BlackRock heads into its May 20 earnings call with short sellers paring positions and a wall of analyst upgrades at its back — yet the stock still trades at a double-digit discount to the Street's consensus target.
The most striking development of the past month was the synchronized target-price raise on April 15, the day after Q1 results. Every major covering analyst lifted their number: Goldman Sachs pushed to $1,313, Morgan Stanley to $1,393, Barclays to $1,310, and UBS to $1,270 — all maintaining positive ratings. The lone dissent came from JPMorgan, which cut its target from $1,269 to $1,128 two days earlier while holding Neutral, a note of caution in what was otherwise a broadly bullish reception to the print. The mean target now sits at $1,254, implying roughly 15% upside from Friday's close of $1,092. The consensus is tilted constructively, though JPMorgan's Neutral acts as a visible anchor on the bull thesis.
Short positioning tells a picture of retreating rather than building conviction on the bear side. Short interest as a percentage of free float is just 1.1% — a level too modest to signal structural concern — but the week's direction is telling: positions dropped 10.5% over five sessions, unwinding a mid-April build that had briefly pushed shares short above 1.9 million. The retreat coincides neatly with the post-earnings price recovery; the stock is up 4.2% on the week and 9.3% over the past month. Borrow costs are correspondingly relaxed at 0.29% annualised, down nearly half from a month ago, and lending availability remains extremely wide — there is no shortage of supply for anyone still wanting to establish a short. The ORTEX short score of 29.6 sits well below the midpoint of its 0-100 range, reinforcing that this is not a name where short pressure is a dominant narrative.
Options positioning is more structurally cautious than the short book, though not at an extreme. The put/call ratio is running at 1.39, essentially in line with its 20-day mean of 1.38 — a z-score of just 0.09 means this week's reading is unremarkable against recent history. What is notable is where that mean sits relative to the 52-week range: the PCR has ranged from 0.87 to 2.07 over the past year, and the current level of sustained put-heavy skew reflects persistent hedging in a name with elevated carry. This is a stock that options participants habitually protect; the lack of any recent spike suggests no incremental panic into the upcoming print.
The fundamental backdrop provides ballast for the bullish lean. Forward earnings estimates have drifted higher, with the 30-day EPS momentum percentile rank at 73 and the 12-month forward EPS year-on-year growth rank at 94 — near the top of the universe. The stock's history of beating consensus estimates ranks in the 82nd percentile on EPS surprise. Valuation multiples have expanded modestly over the past month — P/E has moved from roughly 18.8x to 19.6x — consistent with a market that is gradually re-rating the name after Q1 reassurance. At 19.6x earnings and 3.2x book, the stock is not cheap, but the EV/EBITDA of 13.2x has actually contracted slightly over 30 days, keeping the picture from looking stretched. The dividend score ranks in the 97th percentile, a reminder that income-seeking holders add a floor of structural demand.
One angle worth noting is the insider register. Founder and CEO Larry Fink sold approximately $35.6 million of stock across multiple tranches on April 28, while President Rob Kapito sold a further $9.2 million the same week. Both transactions carry modest trade-significance scores and are consistent with scheduled portfolio management rather than a change in fundamental view, but the timing — at the highest price levels in months and ahead of the next earnings call — is worth logging. The net 90-day insider flow remains a gross seller of roughly $115 million in value, a figure that has been a persistent feature of the ownership picture rather than a new development.
The next marker is the May 20 earnings call. The past two prints have both triggered positive 1-day moves of around 2.3-2.4%, with modest follow-through over five days. That record makes the event less of a binary than many names at comparable valuations. Whether the Q2 print sustains the organic base-fee momentum that the Street rewarded in April, and whether the HPS integration is producing the fee-rate lift analysts are pencilling in, is where attention is most likely to land.
See the live data behind this article on ORTEX.
Open BLK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
